EuroPCR 22: EASTBOURNE Registry LBCT interview

 Bernardo Cortese (Fondazione Ricerca e Innovazione Cardiovascolare, IT) discusses the main findings from the EASTBOURNE Study, that investigated the sirolimus-coated balloon in an all-comer population.

Findings are positive as regards the device’s safety and efficacy profile, with the primary endpoint of target lesion revascularization (TLR) occurring in 6% of the population.

Full interview available here:

https://www.radcliffecardiology.com/video-index/europcr-22-eastbourne-registry-indicates-satefy-sirolimus-coated-balloon

 

EuroPCR 2022 – First Symposium- Current Role of Paclitaxel-DCB in PCI

Fondazione RIC is inviting you.

It is a real pleasure and honor, to share and invite you at the first co-sponsorized symposium on paclitaxel DCB, during EuroPCR 2022. The Course will have the top-in-class Experts on the DCB technology, and will be held in ROOM 252B, Wednesday 18th, 16.30-17.30. Join us if you are attending this years’ EuroPCR!

Home – Fondazione RIC

 

 

Course Programme @ https://bit.ly/3OY2nkw

Presentation of MagicTouch sirolimus coated balloon session at EuroPCR 2021

Watch this session presented by Antonio Colombo, Bernardo Cortese and Sandeep Basavarajaiah in order to understand the strategy behind using a #DrugCoatedBalloon as a proper solution for CAD and the result and potential of using a Sirolimus DCB in coronary intervention, as well as to get insights into a real-world experience with the #MagicTouch in current clinical practice. #SirolimusCoatedBalloon #EuroPCR PCR